Photo Credit: IANS
IANSLive
Hyderabad, May 3 (IANS) A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
For susbcription contact
UoH startup develops stem cell-based treatment for COVID-19
By IANS| Posted by Neha | Updated: 3rd May 2021 11:15 pm IST University of Hyderabad
Hyderabad: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for COVID-19 patients.
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 ‘cytokine storm’, with significantly improved patient survival and time to recovery.
Hyd varsity startup develops stem cell-based treatment for Covid
By IANS |
Published on
Mon, May 3 2021 22:48 IST |
4 Views
University of Hyderabad to allow 2K more students on campus. Image Source: IANS News
Hyderabad, May 3 : A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the Covid-19 cytokine storm , with significantly improved patient survival and time to recovery.